DB:34LA

Stock Analysis Report

Executive Summary

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases.


Snowflake Analysis

Adequate balance sheet with limited growth.

Share Price & News

How has Alpine Immune Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 34LA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-10.6%

34LA

11.7%

DE Biotechs

9.9%

DE Market


1 Year Return

-63.4%

34LA

-8.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: 34LA underperformed the German Biotechs industry which returned -8.1% over the past year.

Return vs Market: 34LA underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

34LAIndustryMarket
7 Day-10.6%11.7%9.9%
30 Day-23.1%-5.9%-16.6%
90 Day-35.3%-22.6%-24.8%
1 Year-63.4%-63.4%-7.9%-8.1%-15.0%-17.5%
3 Yearn/a16.6%15.4%-17.4%-24.5%
5 Yearn/a-6.1%-8.5%-16.6%-28.1%

Price Volatility Vs. Market

How volatile is Alpine Immune Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Alpine Immune Sciences undervalued compared to its fair value and its price relative to the market?

1.33x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 34LA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 34LA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 34LA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 34LA is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 34LA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 34LA is good value based on its PB Ratio (1.3x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Alpine Immune Sciences forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

4.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 34LA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 34LA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 34LA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 34LA's revenue (78.4% per year) is forecast to grow faster than the German market (4.1% per year).

High Growth Revenue: 34LA's revenue (78.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 34LA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Alpine Immune Sciences performed over the past 5 years?

-79.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 34LA is currently unprofitable.

Growing Profit Margin: 34LA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 34LA is unprofitable, and losses have increased over the past 5 years at a rate of -79.1% per year.

Accelerating Growth: Unable to compare 34LA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 34LA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 34LA has a negative Return on Equity (-134.5%), as it is currently unprofitable.


Next Steps

Financial Health

How is Alpine Immune Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: 34LA's short term assets ($52.5M) exceed its short term liabilities ($13.7M).

Long Term Liabilities: 34LA's short term assets ($52.5M) exceed its long term liabilities ($16.2M).


Debt to Equity History and Analysis

Debt Level: 34LA's debt to equity ratio (12.7%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 34LA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: 34LA has a low level of unsold assets or inventory.

Debt Coverage by Assets: 34LA's debt is covered by short term assets (assets are 11.8x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 34LA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 34LA has less than a year of cash runway if free cash flow continues to reduce at historical rates of -61.3% each year


Next Steps

Dividend

What is Alpine Immune Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 34LA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 34LA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 34LA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 34LA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 34LA's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Mitch Gold (51yo)

3.67s

Tenure

US$1,045,690

Compensation

Dr. Mitchell H. Gold, also known as Mitch, M.D., has been Executive Chairman and Chief Executive Officer at Alpine Immune Sciences Inc. since January 2015 and June 2016 respectively. Dr. Gold served as the ...


CEO Compensation Analysis

Compensation vs Market: Mitch's total compensation ($USD1.05M) is above average for companies of similar size in the German market ($USD431.45K).

Compensation vs Earnings: Mitch's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Mitchell Gold
Executive Chairman & CEO3.67yrsUS$1.05m0.0069% $2.9k
Stanford Peng
President and Head of Research & Development0.83yrUS$2.04mno data
Paul Rickey
Senior VP2.83yrsno datano data
Wayne Gombotz
Chief Technology Officer0.67yrno datano data
Kristine Swiderek
Senior Vice President of Research2.25yrsno datano data
Jan Hillson
Senior Vice President of Clinical Development1.17yrsno datano data

1.7yrs

Average Tenure

51yo

Average Age

Experienced Management: 34LA's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Mitchell Gold
Executive Chairman & CEO3.67yrsUS$1.05m0.0069% $2.9k
Robert Conway
Independent Director2.67yrsUS$110.37k0.081% $34.0k
Paul Sekhri
Independent Director2.67yrsUS$107.87kno data
James Topper
Independent Director3.67yrsUS$105.37kno data
Peter Thompson
Independent Director3.67yrsUS$104.12kno data
Jay Venkatesan
Director3.67yrsUS$198.40k0.32% $133.7k
Andrew Scharenberg
Scientific Advisory Board Chairmanno datano datano data
Christopher Peetz
Independent Director1.83yrsUS$68.21kno data
Manish Butte
Member of Scientific Advisory Boardno datano datano data
Paul Tumeh
Member of Scientific Advisory Boardno datano datano data

3.7yrs

Average Tenure

57yo

Average Age

Experienced Board: 34LA's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.8%.


Top Shareholders

Company Information

Alpine Immune Sciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Alpine Immune Sciences, Inc.
  • Ticker: 34LA
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$46.469m
  • Listing Market Cap: US$42.120m
  • Shares outstanding: 18.59m
  • Website: https://www.alpineimmunesciences.com

Number of Employees


Location

  • Alpine Immune Sciences, Inc.
  • 201 Elliott Avenue West
  • Suite 230
  • Seattle
  • Washington
  • 98119
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
34LADB (Deutsche Boerse AG)YesCommon StockDEEURJul 2017
ALPNNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJul 2017

Biography

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 00:02
End of Day Share Price2020/03/30 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.